Adjuvant trastuzumab in breast cancer: Experience from the University of Florence

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 115-118

  Livi, Lorenzo ^a   Borghesi, S ^b   Meattini, I ^a   Saieva, C ^c   De Luca Cardillo, C ^a   Scotti, V ^a   Mangoni, M ^a   Galardi, A ^a   Cataliotti, L ^a   Paiar, F ^a   Bianchi, S ^a   Biti, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Arezzo Hospital   (Italy)

^c ISPO   (Italy)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Breast cancer; Herceptin; Target therapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; EPISTAXIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ITALY; KERATITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; NAUSEA; NEUTROPENIA; ONICOPATHY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRURITUS; RECURRENT DISEASE; RHINORRHEA; SKIN DEFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 77951544009     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.115     Document Type: Article

References (22)

1. Demonty G, Bernard-Marty C, Puglisi F. Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007; 43:497-509.
2. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI. Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu- overexpressing breast cancer: A systematic review. Cancer Treat Rev 2008; 34:539 57.
3. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA et al. Cardiac Safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26:1231-1238.
4. O'Reilly SM, Branes DM, Camplejohn RS, Bartktova J, Gregory MA, Richards MA. The relationship between c-erhB-2 expression, - phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63:444-446
5. Gonzalez-Angulo, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for Her-2/neu-positive breast cancer. Oncologist 2006; 11:857-867
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N EngI J Med 2007; 357:39 51.
7. Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta 2008; 1786:105-113
8. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 2008: 44:2806-2812
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N EngI J Med 2005; 353: 1673-1684
10. Viani GA, Afonso SL, Stefano Ed, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a mata-analysis of published randomized trials. BMC Cancer 2007; 7:153.
11. Smith I. Procter M. Gelber RD, Guillaume S, Fayereislova A. Dowsett M et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 2007; 369: 29-36.
12. Gennari R. Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650-5655
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N EngI J Med 2005; 353:1659-1672
14. Fromm S. Bartsch R, Rudas M, de Vries A, Wenzel C, Sieges GG et al. Factors influencing the time to development of brain metastases in breast cancer. Breast 2008; 17:512-516
15. Francis P. Crown J. Di Leo A, Buyse M, Balil A, Andersson M et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133
16. Andre F, Brogilo K, Roche H, Martin M, Mackey JR, Penault-Llorca F et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008; 26:2636 43.
17. Slamon D, Eiermann W, Robert N, Pienkowski T. Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC > T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC > TH) with docetaxel, carboplatin, and trastuzumab (TCH] in HER2 positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005; 94(S1): A1.
18. Slamon D. Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M et al. BCIRG 006: 2nd interim analysis phase Ill randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients[abstract]. 29th Annual San Antonio Breast Cancer Symposium, Decembar 14-17, 2006, San Antonio, Texas. A52.
19. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewar M, Keefe D et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-ovcrcxprcssing breast cancer: NSABP B-31. J Chin Oncol 2005; 23:7811-7819
20. Sledge GWONA, Thor A, Kahanic SP, Zander PJ, Davidson N. Group ftECO Adjuvant trastuzumab: long-term results of E2198. Breast Cancer Res Treatment 2006; 100(S1]:A2075.
21. Telli LM, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-3533
22. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for nauregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394-398.